Title of article
Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: Results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic urial
Author/Authors
Robert P. Giugliano، نويسنده , , Matthew T. Roe، نويسنده , , Robert A. Harrington، نويسنده , , C. Michael Gibson، نويسنده , , Uwe Zeymer and PENTUA Investigators، نويسنده , , Frans Van de Werf، نويسنده , , Kenneth W. Baran، نويسنده , , Hans-Peter Hobbach، نويسنده , , Lynn H. Woodlief، نويسنده , , Karen L. Hannan، نويسنده , , Sally Greenberg، نويسنده , , Joanne Miller، نويسنده , , Michael M. Kitt، نويسنده , , John Strony، نويسنده , , Carolyn H. ، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2003
Pages
10
From page
1251
To page
1260
Abstract
Objectives
The goal of this study was to evaluate combinations of eptifibatide with reduced-dose tenecteplase (TNK) in ST-elevation myocardial infarction (STEMI).
Background
Glycoprotein IIb/IIIa inhibitors enhance thrombolysis. The role of combination therapy in clinical practice remains to be established.
Methods
Patients (n = 438) with STEMI <6 h were enrolled. In dose-finding, 189 patients were randomized to different combinations of double-bolus eptifibatide and reduced-dose TNK. In dose-confirmation, 249 patients were randomized 1:1 to eptifibatide 180 μg/kg bolus, 2 μg/kg/min infusion, and 180 μg/kg bolus 10 min later (180/2/180) plus half-dose TNK (0.27 mg/kg) or standard-dose (0.53 mg/kg) TNK monotherapy. All patients received aspirin and unfractionated heparin (60 U/kg bolus; infusion 7 U/kg/h [combination], 12 U/kg/h [monotherapy]). The primary end point was Thrombolysis In Myocardial Infarction (TIMI) grade 3 epicardial flow at 60 min.
Results
In dose-finding, TIMI grade 3 flow rates were similar across groups (64% to 68%). Arterial patency was highest for eptifibatide 180/2/180 plus half-dose TNK (96%, P = 0.02 vs. eptifibatide 180/2/90 plus half-dose TNK). In dose-confirmation, this combination, compared with TNK monotherapy, tended to achieve more TIMI 3 flow (59% vs. 49%, P = 0.15), arterial patency (85% vs. 77%, P = 0.17), and ST-segment resolution (median 71% vs. 61%, P = 0.08) but was associated with more major hemorrhage (7.6% vs. 2.5%, P = 0.14) and transfusions (13.4% vs. 4.2%, P = 0.02). Intracranial hemorrhage occurred in 1.0%, 0.6%, and 1.7% of patients treated with any combination, eptifibatide 180/2/180 and half-dose TNK, and TNK monotherapy, respectively.
Conclusions
Double-bolus eptifibatide (180/2/180) plus half-dose TNK tended to improve angiographic flow and ST-segment resolution compared with TNK monotherapy but was associated with more transfusions and non-cerebral bleeding. Further study is needed before this combination can be recommended for general use.
Keywords
cTfc , TNK , corrected Thrombolysis In Myocardial Infarction frame count , tenecteplase , intracranial hemorrhage , INTEGRITI , Integrilin and Tenecteplase in Acute Myocardial Infarction trial , MI , myocardial infarction , PCI , Percutaneous coronary intervention , STEMI , ST-elevation myocardial infarction , aPTT , TIMI , activated partial thromboplastin time , Thrombolysis In Myocardial Infarction , CABG , TMPG , Coronary Artery Bypass Graft Surgery , Thrombolysis In Myocardial Infarction myocardial perfusion grade , ICH
Journal title
JACC (Journal of the American College of Cardiology)
Serial Year
2003
Journal title
JACC (Journal of the American College of Cardiology)
Record number
597909
Link To Document